This test is most useful if any of these apply to you.
A complete blood count with differential tells you how many neutrophils you have. It doesn't show whether those cells can switch on one of their main killing systems. That second question matters when bacterial or fungal infections keep coming despite a normal count.
When a neutrophil swallows a microbe, it fires off a burst of germ-killing oxygen chemicals to destroy it. When that burst is missing, ordinary bacteria and fungi turn dangerous. When neutrophils fire too much in the wrong place, the same chemistry can damage your own tissue.
Neutrophils are the most common white blood cell, made in your bone marrow and sent out to hunt microbes. This test looks at neutrophil oxidative burst, also called the respiratory burst. In this function, a neutrophil switches on NADPH oxidase and makes reactive oxygen species. These are unstable oxygen chemicals that help kill bacteria and fungi.
Most clinical versions use fresh sodium-heparin whole blood from a blood draw. In the lab, neutrophils are given a trigger such as PMA or fMLP, and a fluorescent dye lights up as the oxygen burst rises. Results usually come back as the share of neutrophils that respond, the brightness of that response, or how much higher the signal is after stimulation than at rest. There is no single universal number for normal, because labs use different triggers, dyes, and reporting scales.
This is a specialty functional test. For chronic granulomatous disease, it is a clinically established diagnostic test. For COVID-19, cardiovascular disease, kidney disease, and longevity use, it is still exploratory. Read those results as a functional snapshot from one lab, not as a number to compare across clinics.
The clearest reason to run this test is chronic granulomatous disease (CGD), an inherited defect in the NADPH oxidase machinery. The neutrophils are present in normal numbers, but they cannot mount the oxidative burst, so they cannot finish killing certain bacteria and fungi. The result is repeated, severe, hard-to-clear infections and clusters of inflamed tissue called granulomas, often starting in childhood.
For CGD, DHR oxidative-burst testing is the clinical standard first functional test. A near-absent or clearly impaired burst shows that neutrophils cannot run the NADPH oxidase system and points to genetic testing, family testing, and long-term protective care.
Several COVID-19 studies measured neutrophil ROS with research or bedside assays rather than the standard DHR report. In one rapid blood assay, severe COVID-19 samples produced roughly nine times more neutrophil-derived reactive oxygen species than healthy donor samples. A separate whole-blood flow study found a split pattern: circulating neutrophils looked constantly activated, yet responded poorly when challenged with a bacterial signal.
That split carried weight. Across intensive care patients, those who did not survive showed the greatest loss of the stimulated burst, a pattern that looks like neutrophil exhaustion. A rapid bedside version of the test tracked this: the burst generally settled toward normal in survivors and stayed abnormal in those who died.
Low burst capacity is not always reassuring. In a study of 201 people with cardiovascular disease, researchers used an isolated-neutrophil oxygen-use assay rather than a standard DHR report. People with the weakest burst capacity were about 3.7 times as likely to develop an infection over follow-up. They also had more major cardiac events before adjustment.
The heart-event link weakened once the analysis accounted for anemia and other conditions, so it is not clear whether a weak burst directly drives outcomes or simply flags a sicker, more depleted immune system. Either way, in that study a low functional reserve read as a body less able to defend itself.
In people on hemodialysis, a pooled analysis found neutrophils holding a substantially higher resting output of reactive oxygen species while their ability to swallow microbes fell. These were mostly research assays, not DHR cutoffs you can use as a personal target. The pattern still matters: constant background firing plus weaker cleanup is one proposed reason dialysis patients face both more infections and more cardiovascular damage.
By now the pattern seems to contradict itself. A missing burst is bad in CGD and in some cardiovascular disease studies. An overactive burst is bad in severe COVID-19, brain injury, and dialysis. Both cannot be worse. The way out is to stop treating this as a good-number, bad-number marker. It is a readout of a function, and a function can fail in two opposite ways. Too little firing leaves you defenseless against microbes. Too much, or firing aimed at the wrong target, turns the same chemistry against your own blood vessels and organs. The healthy state is a burst that switches on hard against a real microbe and switches off cleanly afterward. Context, not direction, tells you what a result means.
The single biggest trap is acetaminophen. It suppresses the oxidative burst directly, and it does so fast. A single ordinary dose made the standard DHR burst test look abnormal in all 15 healthy adults within two hours, and 22.1% of hospitalized patients tested within three days of taking it had falsely abnormal results. Avoid acetaminophen for at least 24 hours before testing.
The sample itself matters too. This test uses living whole-blood cells, so delays, cold storage, hemolysis, the wrong tube, or too few neutrophils can distort the result. Many labs require same-day or next-day arrival at room temperature, and some ask for a healthy control sample drawn at about the same time.
Recent physical stress can also shift a reading temporarily. Vigorous exercise pushes primed neutrophils into circulation that may fire harder when tested. Recent surgery and acute illness can raise or suppress the burst depending on timing. None of these mean your neutrophils are diseased; they mean the timing was wrong.
Because this test measures a live cell function rather than a stable molecule, it moves with your day, your medications, specimen handling, and your recent health. A single value caught during an infection, after a workout, or a few hours after a painkiller can point you in the wrong direction.
If you are using it to track something over time, get a clean baseline when you are well and off acetaminophen, then repeat under the same conditions rather than reacting to one result. For suspected CGD, a clearly abnormal burst is not the finish line either. It is the trigger for confirmatory workup, often including repeat burst testing with more than one trigger, myeloperoxidase evaluation when needed, and genetic testing.
An unexpectedly low burst, especially alongside a history of repeated serious bacterial or fungal infections, should be repeated after confirming you took no acetaminophen and are free of acute illness. If it stays low, the next steps are specialized: a follow-up burst test using more than one trigger, staining or other testing for related enzymes such as myeloperoxidase to rule out mimics, and genetic testing for the NADPH oxidase genes. This is an immunology workup.
It also helps to read this test next to its neighbors. A complete blood count with differential shows how many neutrophils you have, which is a different question from whether they work. High-sensitivity C-reactive protein shows whether your body is currently inflamed, which can explain a revved-up reading. Interpreted together, these tell you whether you are looking at a true functional defect, a temporary activation state, or a false alarm.
Evidence-backed interventions that affect your Neutrophil Function, Oxidative Burst level
Neutrophil Function, Oxidative Burst is best interpreted alongside these tests.